Reports indicated that tricyclic antidepressants elevate and reduce glucose and insulin levels, respectively, in humans and animals, contributing to greater metabolic risks in nondiabetic patients with depression or the deterioration of glucose metabolism in individuals with depression and type 2 diabetes through the aggravation of glucose intolerance [65,66,67]. This evidence concerns the gene INS and major depressive disorder.